GEN Exclusives

More »

GEN News Highlights

More »
Mar 5, 2007

Stemagen Acquires Rights to Uniparental Embryonic Stem Cell from UPenn

  • Stemagen acquired the exclusive rights to a patent for uniparental embryonic stem cells from the University of Pennsylvania. Because these stem cells are created without fertilization, they may represent an acceptable alternative for those who oppose the traditional method that requires the use of embryos that are potentially capable of reproduction, the company reports.

    “Because Stemagen has been successful in developing human uniparental embryonic stem cell lines, we believe we are uniquely positioned to capitalize on this patent,” said Stemagen CEO Samuel H. Wood, M.D., Ph.D.


GEN Jobs powered by connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
More »

Be sure to take the GEN Poll

Disclosing Clinical Trial Data

Do you believe that conducting performance audits for new drugs will incentivize pharma firms to become more transparent?

More »